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B-crystallin is a member of the heat shock protein family that exerts cell protection under several stress-related conditions. Recent
studies have revealed that B-crystallin plays a beneficial role in a mouse model of multiple sclerosis, brain ischemia, and Alexander
disease. Whether B-crystallin plays a role in modulating the secondary damage after CNS trauma is not known. We report here that
B-crystallin mediates protective effects after spinal cord injury. The levels of B-crystallin are reduced in spinal cord tissue following
contusion lesion. In addition, administration of recombinant human B-crystallin for the first week after contusion injury leads to
sustained improvement in locomotor skills and amelioration of secondary tissue damage. We also provide evidence that recombinant
human B-crystallin modulates the inflammatory response in the injured spinal cord, leading to increased infiltration of granulocytes
and reduced recruitment of inflammatory macrophages. Furthermore, the delivery of recombinant human B-crystallin promotes
greater locomotor recovery even when the treatment is initiated 6 h after spinal cord injury. Our findings suggest that administration of
recombinant humanB-crystallinmay be a good therapeutic approach for treating acute spinal cord injury, for which there is currently
no effective treatment.
Introduction
Injury to the spinal cordresults in immediatedamagecauseddirectly
by the trauma, followed by a secondary phase of tissue degeneration
that occurs over a period of several weeks, which contributes signif-
icantly to functional impairment (SchwabandBartholdi, 1996;Oya-
domari et al., 2002). Multiple mechanisms contribute to secondary
damage, not all of which are fully defined (Kwon et al., 2004; Pop-
ovichandLongbrake, 2008). Inaddition tomechanisms that actively
induce secondary damage, lack of effective protective responses that
block secondary damage or mediate repair can also contribute to
tissue damage and functional loss (Kwon et al., 2004; Popovich and
Longbrake, 2008). The final outcome after injury will therefore de-
pend on the balance between the harmful and protective responses.
Activating endogenous protectivemechanisms in spinal cord injury
(SCI) can therefore be expected to reduce secondary damage and
minimize functional deficits.
Heat Shock Proteins (Hsp) are among the most highly ex-
pressed cellular proteins across all species (Lindquist and Craig,
1988). Hsp act as molecular chaperones and protect cells by pre-
venting protein misfolding and aggregation (Morange, 2005). In
the CNS, some members of the Hsp family are upregulated and
exert protection (Muchowski and Wacker, 2005). The beneficial
functions of Hsp in the CNS include prevention of protein aggre-
gation, refolding of partially denatured proteins, inhibiting cell
death pathways, and modulating the inflammatory response
(Muchowski and Wacker, 2005; Brown, 2007).
B-crystallin (CRYAB) is a small Hsp family member closely
related to Hsp27 (Ingolia and Craig, 1982). CRYAB is constitu-
tively expressed in many tissues and is especially abundant in eye
lens, heart, andmuscles (Arrigo et al., 2007). Several studies have
demonstrated that CRYAB mediates cell protection under vari-
ous stress conditions (Arrigo et al., 2007).Moreover, humanmu-
tations in the CRYAB gene have been associated with cataracts
(Safieh et al., 2009; Chen et al., 2010) and several myopathies
(Goldfarb and Dalakas, 2009; Del Bigio et al., 2011). In the CNS,
CRYAB is constitutively expressed in oligodendrocytes; never-
theless, its expression is found in other glial cells in multiple
sclerosis and brain ischemia (Piao et al., 2005; Ousman et al.,
2007). It is also found in inclusion bodies in many protein con-
formation disorders such as Alexander disease, Alzheimer dis-
ease, and Parkinson disease (Muchowski and Wacker, 2005;
Arrigo et al., 2007). Little is known about the role of CRYAB in
the CNS. Recent studies have revealed a protective role for
CRYAB in a mouse model of multiple sclerosis [experimental
autoimmune encephalomyelitis (EAE)], stroke (Arac et al.,
2011), and Alexander disease (Ousman et al., 2007; Hagemann et
al., 2009). In EAE, CRYAB acts as a negativemodulator of inflam-
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mation and prevents demyelination and disease symptoms (Ous-
man et al., 2007). In Alexander disease, however, beneficial
functions of CRYAB aremediated by preventing proteinmisfold-
ing and aggregation (Hagemann et al., 2009). At present, the
expression and role of CRYAB after CNS trauma has not been
reported. Here, we report for the first time whether CRYAB con-
fers protection in SCI in mice.
Materials andMethods
Spinal cord contusion injury.All surgical procedureswere approved by the
Universitat Auto`noma de Barcelona Animal Care Committee and the
McGill University Animal Care Committee, and followed the guidelines
of the European Commission onAnimal Care and the Canadian Council
on Animal Care. Adult (8–10 weeks old) female C57BL/6 mice (Charles
River) were anesthetized with ketamine:xylazine:acepromazine (100:
10:3 mg/kg). After performing a laminectomy at the 11th thoracic verte-
brae, the exposed spinal cord was contused using the Infinite Horizon
Impactor device (Precision Scientific Instrumentation). Injuries were
made using a force of 60 kdynes and tissue displacement ranging between
500 and 700 m.
Recombinant human B-crystallin (rhCRYAB; US Biologicals) was
diluted in sterile saline and mice injected intravenously with 10 g of
rhCRYAB in 100 l of total solution. This dose was previously shown to
be effective in EAE and stroke (Ousman et al., 2007; Arac et al., 2011).
The total amount of endotoxins administrated intravenously per mouse
was 0.5 EU/kg body weight/d, lower than themaximum endotoxin levels
set by the FDA for injectable drugs (5 EU/kg body weight/h). Control
mice were injected with an equal volume of sterile saline. Mice were first
injected 1, 6, or 12 h after SCI and injections were repeated daily there-
after until day 7.
To trace which cells uptake CRYAB in SCI, another group of mice
received 10 g of recombinant human GST-tagged CRYAB in 100 l of
saline.
Functional assessment. Locomotor recovery was evaluated in an open-
field test using the nine-point Basso Mouse Scale (BMS) (Basso et al.,
2006), which was specifically developed for locomotor testing after con-
tusion injuries in mice. The BMS analysis of hindlimb movements and
coordination was performed by two independent assessors and the con-
sensus score taken. The final score is presented as mean SEM.
Western blotting. A 5 mm length of spinal cord tissue containing the
lesion site was collected from uninjured mice and at 1, 3, 7, 14, 21, and
28 d postinjury (dpi) (n  3 per time point). To reduce variability in
protein solubilization, samples were homogenized simultaneously in
10% NP-40, 1% deoxycholate, 0.1% SDS in PBS containing Complete
Protease and Phosphatase inhibitor Cocktail (Roche Applied Science).
After centrifugation at 15,000 g for 20 min at 4°C, supernatants were
isolated and protein concentrations determined using the Bio-Rad Pro-
tein Assay. Protein samples (30g) were separated by electrophoresis on
a 10–15% polyacrylamide gel and transferred onto PVDF membranes
(Millipore). Each polyacrylamide gel was loaded with individual protein
samples from each of the different time points.
In addition, injured spinal cords were obtained at 12, 24, and 72 h
postinjury from mice treated with rhCRYAB or saline (n 4 per group
and time point) and were homogenized using the same protocol.
The membranes were incubated with rabbit antibodies against
CRYAB (1:250; Assay Designs), NF-kB p50/105 (1:200; Cell Signaling
Technology), I-B (1:200; Cell Signaling Technology), and C/EBP ho-
mologous protein (CHOP; 1:100; Santa Cruz Biotechnology). Bands
were detected using Chemiluminescence (Immobilon Western Chemi-
luminescence HRP reagent; Millipore) and the data quantified by densi-
tometry using Gene Snap and Gene Tools software in a Gene Genome
apparatus (Syngene). -actin (1:10,000; Sigma Aldrich) was used to en-
sure equal loading of samples.
Histology.Naive and injured mice were perfused with 4% paraformal-
dehyde in 0.1 M-phosphate buffer (PB) at 12 h and 3 and 28 dpi. A 5 mm
length of spinal cord containing the lesion site was removed, cryopro-
tected with 30% sucrose in 0.1 M PB at 4°C, and six series of 15-m-thick
sectionwere picked up on glass slides. Adjacent sections on the same slide
were therefore 90 m apart. For immunofluorescence, tissue sections
were rehydrated in PBS and blocked in 5% serum in TBS with 0.5%
Triton X-100 for 1 h. The sections were then incubated overnight at 4°C
with rabbit anti-CRYAB (1:500; Assay Designs) or rabbit anti-GST (1:
250; Abcam) combined with antibodies against GFAP (for astrocytes;
1:500; Zymed), NeuN (for neurons; 1:200; Millipore), CC1 (for oligo-
dendrocytes; 1:50; Calbiochem), Iba1 (for macrophage/microglia; 1:250;
Abcam), Gr1 (for granulocytes; 1:100; Invitrogen), and CD31 (for endo-
thelial cells; 1:100; Acris Antibodies). After several washes in PBS, sec-
tions were incubated for 1 h at room temperature with the appropriate
Alexa 594- or Alexa 488-conjugated secondary antibodies (1:500; Invit-
rogen) and then coverslipped inMowiol containingDAPI to label nuclei.
CRYAB oligodendrocytes were manually quantified in tissue cross-
sections in a 7.5 104 m2 area in the lateral and dorsal columns from
five tissue sections of uninjured and contused spinal cord at day 7 postin-
jury and the percentage of CC1 oligodendrocytes expressing CRYAB
were averaged from these sections (n 3 per time point). Quantification
of CC1 and CRYAB cells in the contused spinal cord was done at the
epicenter and in cord sections located at 270 and 570 m rostral and
caudal, to the injury epicenter. Quantification of cells that have taken up
rhCRYAB was performed from saggital spinal cord tissue sections har-
vested at 12 h postinjury frommice injected with GST-tagged rhCRYAB.
Cells double-stained with GST cells and GFAP, NeuN, or CC1 were
manually counted in an area of 7.5  104 m2 at both lateral and ros-
trocaudal edges of the lesion. Three spinal cord tissue sections were an-
alyzed per mouse (n  3). Histopathological analyses of the injured
spinal cord were performed from tissue samples harvested at day 28.
Images were acquired with the aid of a digital camera attached to the
microscope (Olympus) and then analyzed using NIH ImageJ software
(NIH, Bethesda, MD). Tissue sparing was calculated by delineating the
GFAP-stained areas (GFAP-positive tissue), and neuronal survival as-
sessed bymanually counting the NeuN-positive cells in the ventral horn.
Double immunostaining against NF (1:1000; Millipore) and MBP (1:
100; Abcam) was performed to assess axonal andmyelin sparing. Assess-
ment of axonal sparing was performed by counting the axons in the
dorsal columns at the injury epicenter. Myelin sparing or demyelination
in the dorsal column was assessed by counting the fibers double-stained
for NF and MBP at the lesion epicenter. Assessment of astrogliosis was
done by calculating the area of GFAP immunoreactivity in high-
magnification images (40) taken from lateral whitematter at the injury
epicenter and rostral and caudal regions, for a total length of 1800 m.
Two images from the lateral white were taken from each spinal cord
section immunostained for GFAP, and the area of GFAP immunoreac-
tivity was averaged from both images. Eight mice per group were used in
all the histopathological analyses.
Cytokine protein expression. A 5 mm length of spinal cord centered on
the lesion was collected at 12 h after surgery from mice treated with
rhCRYAB or saline (n  4 each group) and snap-frozen. Spinal cords
were homogenized in Tissue Extraction Reagent I (Invitrogen), and pro-
tein concentration was determined using the DC Protein Assay (Bio-
Rad). Samples were concentrated using MicroCon centrifugation filters
(Millipore) and the protein concentration redetermined. All samples
were diluted to 3.7 g/l to ensure equal amounts of protein. The pro-
tein levels of 20 cytokines and chemokines (FGF,GM-CSF, IFN-, IL-1,
IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40/p70, IL-13, IL-17, IP-10,
CXCL1/KC, CCL2/MCP-1, MIG, CCL3/MIP-1, TNF-, and VEGF)
were then analyzed using the BioSource Mouse Cytokine 20-
PlexMultiplex Bead Immunoassay (Invitrogen) on a Luminex-100LS
system as per the manufacturers’ protocol. Results were analyzed using
Beadview multiplex data analysis software (UpState Biotechnology).
Flow cytometry. Immune cells from the injured spinal cord were ana-
lyzed by flow cytometry at 1, 3, and 7 dpi as described previously (Stirling
and Yong, 2008). Briefly, spinal cords were cut in little pieces and passed
through a cell strainer of 40m (BD Falcon) and the cell suspension was
centrifuged twice at 300 g for 10 min at 4°C. After cell counts, samples
were incubated with anti-CD16/CD32 (eBioscience) for 15 min at room
temperature to block the nonspecific binding of immunoglobulins to the
Fc receptors. Samples were divided, and cells alone and isotype-matched
control samples were generated to control for nonspecific binding of
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antibodies and for autofluorescence. Isotype control antibodies were
purchased from eBioscience and included phycoerythrin (PE)-labeled
rat IgG2b, APC-labeled rat IgG2b, and peridinin chlorophyll-a protein
(PerCP)-conjugated rat IgG2b, fluorescein isothiocyanate-conjugated
(FITC) rat IgG2b, and IgG2M. The following antibodies were also pur-
chased from eBioscience: CD45-PerCP, GR1-FITC, CD11b-PE, Ly-6C-
FITC, and F4/80-APC. After 30 min of incubation with combinations of
antibodies at 4°C, the samples were washed and fixed in 1% paraformal-
dehyde. Granulocytes were identified as CD45high, CD11b, and Gr-
1high (Stirling and Yong, 2008).Macrophage/microglia subsets (CD45,
CD11b, F4/80) were further differentiated based on Ly6C expression
(Arnold et al., 2007; Nahrendorf et al., 2007). At least 3000 CD45 cells
were analyzed per spinal cord sample using FlowJo software on a FAC-
SCanto flow cytometer (BD Biosciences).
Statistical analyses. Data are shown as mean  SEM. Changes in the
expression of CRYAB in SCI assessed by Western blot were analyzed by
using one-way ANOVA with post hoc Dunnett’s test. BMS and histolog-
ical data were performed by using two-way repeated-measures ANOVA
with post hoc Tukey’s test for multiple comparisons. Student’s t test was
used for the Western blot and FACS analyses comparing control and
experimental groups.Differenceswere considered significant at p 0.05.
Results
Expression of CRYAB in the injured spinal cord
We first assessed the protein levels of CRYAB in the uninjured
spinal cord and at 1, 3, 7, 14, 21, and 28 d after contusion injury.
Western blot analyses revealed that CRYAB protein levels were
reduced40% at day 1 after SCI, and remained lower than nor-
mal levels for up to day 28 postinjury (Fig. 1A,B). We next as-
sessed cellular localization of CRYAB in naive and injured spinal
cord tissue sections. Double immunofluorescence labeling re-
vealed that CRYAB is expressed in 53.7 2.3% of CC1-positive
oligodendrocytes in the uninjured spinal cord (Fig. 1C–E). At day
7 following contusion, when levels for CRYAB peaked after in-
jury, spinal cord tissue sections from 540 m rostral to 540 m
caudal to the injury epicenter revealed that CRYAB is expressed
in 44.5 3.8% of CC1 cells. We did not observed constitutive
expression of CRYAB in astrocytes (Fig. 1F–H). Following le-
sion, however, CRYAB was detected in GFAP-positive astrocytes
forming the glial scar (Fig. 1 I–K). The death of oligodendrocytes
that occurs after SCI (Crowe et al., 1997) and probably the failure
of the remaining oligodendrocytes to upregulate CRYAB after
injury might be responsible for the reduction of CRYAB levels in
injured spinal cord seen by Western blotting. CRYAB was not
observed in macrophages, granulocytes, neurons, or endothelial
cells (data not shown).
Administration of recombinant human CRYAB enters into
the injured spinal cord
We hypothesized that the loss of CRYAB in the spinal cord tissue
after injury contributes to secondary damage after SCI, and that
exogenous administration of CRYAB may lead to protective ef-
fects. Since injury to the spinal cord leads to blood vessel disrup-
tion and blood–brain barrier breakdown, we assessed whether
intravenous injection of rhCRYAB 1 h postinjury could enter the
injured spinal cord. Western blot analysis of injured spinal cords
revealed that 11 h postinjection (12 h postinjury), protein levels
for CRYAB were approximately twofold greater in mice injected
with rhCRYAB compared with those receiving saline (p 0.05;
Fig. 2A,B). However, CRYAB protein levels in mice treated with
rhCRYABwere still reduced20% compared with physiological
levels in normal uninjured spinal cord (p 0.05; Fig. 2A,B). To
further confirm that the exogenously administered rhCRYAB en-
tered the injured spinal cord and assess which cell types had taken
it up, we injected GST-tagged rhCRYAB. The GST tag allowed us
to distinguish endogenous CRYAB from the rhCRYAB adminis-
tered. GST staining was observed in tissue sections from injured
spinal cords but not in those harvested from uninjured animals,
suggesting that rhCRYAB is only able to reach the injured CNS
(Fig. 2C,D). Histological sections from spinal cord tissue har-
vested at 11 h postinjection (12 h postinjury) immunostained
against GST revealed that rhCRYAB was located in the white
matter at the injury epicenter, and in white and gray matter in
adjacent areas, for a total rostrocaudal length of3mm. In these
areas, double immunofluorescence labeling for GST and cell
type-specific antibodies revealed that rhCRYAB was taken up by
30.7 4.7% of oligodendrocytes, 38.8 5.2% of astrocytes, and
45.1 3.1% of neurons (Fig. 2E–G). rhCRYABwas not found in
microglial cells, granulocytes, or endothelial cells (data not
shown).
Treatment with rhCRYAB promotes recovery after spinal
cord injury
We next examined whether administration of rhCRYAB en-
hances locomotor recovery after SCI. Compared with the saline-
treated mice, those treated with rhCRYAB showed significant
improvement in locomotor recovery [p  0.05; two-way
repeated-measure (RM)-ANOVA with post hoc Tukey’s test; n
8 for both groups; Fig. 3]. Post hoc analysis revealed significant
differences in the BMS score starting at day 5 after injury and
remaining significantly enhanced for the 4weeks of the followup.
At 28 d postinjury, vehicle-treated mice showed no plantar step-
ping (score, 2.8) but showed extensive ankle movements or plan-
tar placement of the paw with or without weight support. In
contrast, all themice treated with rhCRYAB displayed occasional
(40%) or frequent plantar stepping (60%) (score, 4.6) but
lacked coordination.
We then assessed whether the locomotor improvement ob-
served after rhCRYAB administration was associated with ame-
lioration of secondary tissue damage. Histological sections of the
spinal cord labeled with anti-GFAP antibodies revealed that rh-
CRYAB treatment reduced tissue loss at the epicenter of the in-
jury and in adjacent regions (p  0.05; two-way RM-ANOVA
with post hoc Tukey’s test; Fig. 4A–C). We also assessed axonal
loss and demyelination at the dorsal column of the spinal cord at
the epicenter of the injury (Fig. 4D–H). Spinal cord sections
immunolabeled with anti-NF showed that rhCRYAB treatment
resulted in an approximately twofold greater number of spared
axons in the dorsal columns at the epicenter of the lesion (p 
0.02; t test; Fig. 4D,E,G). Furthermore, double immunostaining
against NF and MBP revealed that rhCRYAB administration led
to approximately fivefold greater number of myelinated axons
(p  0.007; t test; Fig. 4D,F,H). We also evaluated whether rh-
CRYAB treatment protected against neuronal loss. Quantifica-
tion of NeuN-positive cells in the ventral horn of the spinal cord
indicated that mice treated with rhCRYAB showed improved
neuronal survival in regions rostral to the injury epicenter for a
total length of 1000 m rostral to the epicenter (p  0.05; two-
way RM-ANOVAwith post hoc Tukey’s test; Fig. 4 I–M). Overall,
these data demonstrate that treatment with rhCRYAB has multi-
ple protective effects in spinal cord injury.
Treatment with rhCRYABmodulates inflammatory
responses in spinal cord injury
Previous studies have shown that CRYAB mediates protection
against protein misfolding and aggregation, which is a patholog-
ical hallmark of many neuropathological disorders (Arrigo et al.,
2007; Hagemann et al., 2009; Bousette et al., 2010). Misfolded
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and aggregated proteins induce cell death, in part, by triggering
the accumulation of the transcription factor CHOP, also known
as GADD153, an endoplasmic reticulum stress inducer of apo-
ptosis (Zinszner et al., 1998; Oyadomari et al., 2002). We there-
fore assessed whether rhCRYAB reduced CHOP levels in SCI
at 3 d following injection, when CHOP levels peak after SCI
(Penas et al., 2007; Ohri et al., 2011). Our results revealed that
rhCRYAB treatment failed to reduce CHOP levels in SCI (data
not shown). These data suggest that the protective mecha-
nisms of rhCRYAB in SCI are unlikely to be mediated by re-
duction of stress response triggered by protein misfolding and
aggregation.
Recent studies suggest that CRYAB modulates inflammatory
response in multiple sclerosis and its mouse model (EAE) and
after brain stroke (Ousman et al., 2007; van Noort et al., 2010;
Arac et al., 2011). We therefore assessed whether rhCRYAB ad-
ministration was able to modulate inflammation in SCI. We first
examined activation of NF-B in SCI, a key nuclear factor in
Figure 1. Expression of CRYAB in spinal cord injury. A, B, Western blot analysis shows reduced CRYAB protein levels after spinal cord injury starting at day 1.-actin is used as a loading control
(n 3mice per time point). ui, Uninjured. C–E, Double immunofluorescence labeling of a cross-section of the uninjured spinal cord for CC1 and CRYAB. Note the colocalization of CRYAB (green) in
oligodendrocytes (red). F–K, Double immunofluorescence labeling for GFAP and CRYAB of a cross-section of uninjured (F–H ) and injured spinal cord (I–K ) harvested at day 7 postinjury. Note that
astrocytes do not express CRYAB in the uninjured cord. However, there is strong CRYAB immunoreactivity (green) in reactive astrocytes (red) at the border of the lesion (L). The areas outlined in the
boxes are shown in higher magnification in the insets. Scale bar, 50m. *p 0.05. Error bars indicate SEM.
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triggering the activation of the neuroinflammatory response. We
found that at 12 h after SCI, mice treated with rhCRYAB dis-
played greater levels of the activated NF-B p50 subunit com-
pared with saline-treatedmice (p 0,05; t test), while the level of
its negative regulator, I-B, remained unchanged (Fig. 5A,B).
We then studied whether the increased NF-B levels observed
after rhCRYAB treatment altered the expression of inflammatory
cytokines and chemokines in the spinal cord at 12 h following
contusion (Fig. 5C). We found that injured spinal cords from
mice treated with rhCRYAB had a marked increase in expression
of four chemokines (CCL1/KC, CCL2/MCP-1, CCL3/MIP-1,
CXCL10/IP-10) and two cytokines (IL-5, IL-6), when compared
with saline-treated mice (n  4 for each group; Student’s t test;
Fig. 5C). Since cytokines and chemokines promote the infiltra-
tion and activation of immune cells, we used FACS analyses to
study whether treatment with rhCRYAB modulated the infil-
tration of myeloid cells in SCI. CD45 was used as a marker for
peripheral immune cells and microglia to sort cells obtained
from injured spinal cords from rhCRYAB and saline-treated
mice. The combination of antibodies against CD45, CD11b,
Gr-1, F4/80, and Ly6C allowed us to discriminate among granulo-
cytes (CD45, CD11bhigh, Gr1high), inflammatory macrophages
(CD45, CD11b, F4/80, Ly6C), and resident macrophages
(CD45, CD11b, F4/80, Ly6C) from blood (Arnold et al.,
2007; Nahrendorf et al., 2007). Our data show a significant increase
Figure 3. Time course of locomotor recovery in mice treated with recombinant human
CRYAB starting 1 h after SCI. Locomotor recoverywas assessed after spinal cord contusion injury
in mice treated with saline or recombinant human CRYAB (n 8 per group) using the BMS.
Administration of recombinant human CRYAB show significant improvement in locomotor per-
formance compared with wild-type mice as early as 5 d after injury. *p 0.05. Error bars
indicate SEM.
Figure 2. Recombinant human CRYAB reaches the injured spinal cord when given intravenously. A, B, Western blot from spinal cords harvested at 12 h following lesion shows increased CRYAB
protein levels in mice injected with recombinant human CRYAB.-actin is used as a loading control (n 4 per group). C–E, Double immunofluorescence for GST and GFAP (C), NeuN (D), and CC1
(E) at 12 h after injury. The areas outlined in the boxes are shown in higher magnification in the insets. Note the presence of the recombinant human CRYAB in astrocytes, neurons, and
oligodendrocytes. GFAP and CC1 images were taken from the ventral white matter, while NeuN staining was taken from the ventral horn of spinal cord tissue sections taken at 270m rostral in
relation to injury epicenter. Scale bar, 50m. *p 0.05. Error bars indicate SEM.
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Figure4. RecombinanthumanCRYABtreatmentamelioratestissuedamage.A,Quantificationoftissuesparingatvariousdistancesrostral(R)andcaudal(C)totheinjuryepicenterrevelssignificantreduction
in tissue loss inmice treatedwith recombinanthumanCRYABat theepicenterof the injuryandadjacent sections.B,C, Representativemicrographs showing tissue sparingat the injuryepicenter inmice treated
with saline (B) or recombinanthumanCRYAB(C).D, Quantificationofaxonandmyelin sparing in thedorsal columnat theepicenterof the injury. Treatmentwith recombinanthumanCRYABresulted ingreater
axonandmyelinpreservation.E–H,Representativemicrographsof thedorsal columnsstainedagainstNF(E,G)andMBP(F,H ) frommicetreatedwithsaline(E,F )andrecombinanthumanCRYAB(G,H ).Note
thegreaterpreservationofaxonsandmyelinatedfibers inmiceadministeredwithrecombinanthumanCRYAB. I,Quantificationofventralhornneuronsurvivalatvariousdistancesrostralandcaudal tothe injury
epicenter reveals significantly greater neuronal survival inmice treatedwith recombinant humanCRYAB. J–L, Representativemicrographs showing sparing of ventral horn neurons inmice administeredwith
saline (J ) and recombinant human CRYAB (L) in sections stained against NeuN at 600m rostral to the injury epicenter. J, L, The areas outlined in the boxes are shown in higher magnification in K and E,
respectively. Scale bars:B, C (in C), 500m; E,G (inG), 125m; F,H (inH ), 25m; J, L (in L), 250m;K,M (inM ), 75m.*p 0.05. Error bars indicate SEM.
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of granulocytes in the spinal cord paren-
chyma of mice injected with rhCRYAB at
day 1 following contusion compared with
those mice treated with saline (n  4; p 
0.004, Student’s t test; Fig. 6A). No differ-
ences were found with regards to the two
types of monocyte populations at this time
point (Fig. 6B).Analyses performedatday3
after injury revealed that therewasnodiffer-
ence in the proportion of granulocytes and
residentmacrophages in the spinal cord be-
tween both experimental groups (Fig. 6).
However, the proportion of inflammatory
macrophages was significantly reduced in
mice treated with rhCRYAB (n  4; p 
0.03, t test; Fig. 6B).We did not observe any
differences regarding these three immune cell populations at day 7
postinjury (data not shown).
We also assessed whether rhCRYAB had any effect on astro-
gliosis. Tissue sections from spinal cord taken at day 28 postin-
jury revealed that treatment with rhCRYAB led to significant
reduction in astroglia reactivity at the injury epicenter and in
adjacent sections (p 0.05; two-way RM-ANOVA with post hoc
Tukey’s test; n 8 for both groups; Fig. 7). Therefore, adminis-
tration of rhCRYAB in SCI modulates immune cell infiltration,
promoting greater entry of granulocytes at day 1 following lesion
and reducing the recruitment of inflammatory macrophages at
day 3, and reduces astrogliosis.
Effects of delayed treatment with rhCRYAB in SCI
We assessed the effectiveness of delaying the onset of rhCRYAB
treatment beyond 1 h after SCI. Two delay treatments were
tested, either starting at 6 or 12 h postinjury. We observed signif-
icant enhancement in locomotor recovery when rhCRYAB treat-
ment was initiated 6 h following contusion. Significant
differences were seen starting at day 7 following injury and re-
mained enhanced until day 28 (n  7 for each group; p  0.05;
two-way RM-ANOVAwith post hoc Tukey’s test; Fig. 8A). How-
ever, this enhancement in locomotor performance when rh-
CRYAB treatment was delayed for 6 h was less than that seen
when treatment was started 1 h postlesion (Fig. 3). The beneficial
effects of rhCRYAB in SCI were further reduced when treatment
was delayed for 12 after SCI (Fig. 8B). Mice receiving rhCRYAB
12 h postinjury show significant improvement in locomotor con-
trol from days 5 to 14 but not at later time points (n 9 for each
group; p 0.05; two-wayRM-ANOVAwith post hocTukey’s test;
Fig. 8B). Histological analysis of tissue sections taken at day 28
postinjury revealed that rhCRYAB promotes tissue sparing when
the treatment is delayed for 6 but not 12 h postinjury (Fig. 8C,D).
Discussion
Stress conditions triggered by injury or disease lead to increase pro-
teinmisfolding and aggregation (Morange, 2005). This is of impor-
tance since theaccumulationofmisfoldedandaggregatedproteins is
a pathological hallmark of several neurodegenerative diseases. Pro-
tein misfolding also occurs in SCI, which triggers the accumulation
of CHOP in neurons and oligodendrocytes, and subsequently their
death (Penas et al., 2007; Ohri et al., 2011). Previous studies have
highlighted the protective role for CRYAB in some CNS condi-
tions where protein misfolding occurs, such as in mouse models
of Alexander disease, multiple sclerosis, brain ischemia, and Alz-
heimers disease (Ousman et al., 2007; Hagemann et al., 2009;
Bousette et al., 2010; Arac et al., 2011; Ojha et al., 2011). Unex-
pectedly, we observed that protein levels of CRYAB are reduced
following SCI. This loss of CRYAB may be due to oligodendro-
cyte cell death that occurs following lesion (Crowe et al., 1997), as
this is the only cell type that expresses CRYAB in the uninjured
spinal cord. However, the absence of CRYAB in neurons, and
probably the failure of oligodendrocytes to increase CRYAB lev-
els following SCI, maymake these cells more vulnerable to death.
The loss of CRYAB in the CNS has been also showed after brain
ischemia (Piao et al., 2005), and in theTg2576mouse (Ojha et al.,
2011), a mouse model of Alzheimer disease. Interestingly,
CRYAB-null Tg2576 mice showed greater exacerbation of pro-
tein aggregation and locomotion impairment compared with
Tg2576, suggesting that the loss of CRYABmay contribute to the
progression of Alzheimer disease (Ojha et al., 2011). Similarly,
CRYAB/ mice underwent greater tissue damage after stroke
(Arac et al., 2011). Here we show that administration of rh-
CRYAB, which is taken up in the spinal cord parenchyma by
oligodendrocytes, neurons, and astrocytes, reduces demyelina-
tion and neuronal cell death following SCI. rhCRYAB treatment,
however, did not reduce CHOP levels after SCI, suggesting that
the beneficial effects of rhCRYAB in SCI may be independent of
protein misfolding and aggregation. Apart from its chaperone
function, someHspsmodulate inflammation (Quintana andCo-
hen, 2005), which is one the major contributors to tissue damage
after SCI (Popovich and Longbrake, 2008; Kwon et al., 2011).
Recent studies revealed that CRYAB might be a negative regula-
tor of inflammation, since mice lacking CRYAB showed exacer-
bated inflammatory response and functional deficits in EAE
(Ousman et al., 2007) and after stroke (Arac et al., 2011). Admin-
istration of rhCRYAB, however, failed to reduce adaptive im-
mune response after brain ischemia, whereas the effects on innate
immune response were not assessed (Arac et al., 2011). Although
it is unknownhow the absence of CRYABmay exacerbate inflam-
mation, it could be due, in part, to the greater susceptibility of
cells to stress due to the lack of this chaperone, since CRYAB/
astrocytes have augmented cell death, ERK, and NF-B signaling
upon TNF- stimulation, but also under resting conditions
(Ousman et al., 2007). Recent observations suggest that CRYAB
may activate the innate immune response, since microglia be-
come activated upon CRYAB stimulation in vitro (van Noort et
al., 2010). These apparently diverging effects of CRYAB on in-
flammation may be due to the ability of this Hsp to act as an
extracellular signal, as shown in other Hsp, such as HSP27 and
HSP70 (Brown, 2007). Indeed, several studies demonstrate that
-crystallin family members are agonist of several receptors in-
volved in the initiation of inflammation, such as protease-
activated receptors (PARs) (Li et al., 2009; Li and Reiser, 2011)
Figure5. Treatmentwith recombinant human CRYABmodulates inflammatory response.A,Western blots showingNF-kB p50
and IkB-expressionat12h following injury inmice treatedwith salineof recombinanthumanCRYAB.-actin is usedasa loading
control (n 4 per group). B, Densitometric values of the Western blot reveal increased expression of NF-kB p50 after treatment
with recombinant human CRYAB. C, Changes in chemokine and cytokine expression in the spinal cord at 12 h following contusion
injury in mice administered with saline or recombinant human CRYAB. Note that treatment with recombinant human CRYAB
resulted in greater expression of IL5, IL6, KC, IP10, MCP1, and MIG. *p 0.05. Error bars indicate SEM.
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and toll-like receptors (TLRs) (Ohashi et al., 2000; Asea et al.,
2002). Although the role of PARs in SCI is unknown, PAR-1 and
PAR-2 exert protection in brain ischemia (Jin et al., 2005; Thiya-
garajan et al., 2008). Similarly, TLR2 andTLR4-nullmice showed
greater functional deficits and myelin loss after SCI (Kigerl et al.,
2007) and impaired axon regeneration after sciatic nerve injury
(Boivin et al., 2007).
Astrocytes play an important role in initiating the inflamma-
tory response following SCI (Pineau et al., 2010), as they are one
of the major contributors to cytokines and chemokine synthesis
(Pineau and Lacroix, 2007; Pineau et al., 2010). Activation of the
immune response by astrocytes appears to be mediated, in part,
by NF-B signaling since inactivation of astroglial NF-B in SCI
results in reduced cytokine expression and inflammation (Bram-
billa et al., 2005). Here we show that astrocytes take up rhCRYAB
when administered intravenously after SCI. Interestingly, astro-
cytes express PARs and TLRs (Kigerl et al., 2009; Li et al., 2009).
Spinal cords harvested at 12 h postinjury revealed that rhCRYAB
treatment led to greater levels in the expression of the active
subunit NF-kB p50, and certain cytokines and chemokines (IL-5,
Figure 6. Altered recruitment of immune cells in the injured spinal cord after treatment with recombinant human CRYAB. A, B, Representative density plots of FACS analysis showing the
infiltration of granulocytes (CD45 high, CD11b, Gr1 high;A) and type I inflammatorymacrophages (CD45, CD11b high, F4/80, Ly6C) and type II anti-inflammatorymacrophages (CD45,
CD11b high, F4/80, Ly6C) (B) at days 1 and 3 following contusion injury. Note that treatment with recombinant human CRYAB results in increased infiltration of granulocytes at day 1 but not
at day 3 following injury compared with mice treated with saline. Administration of recombinant human CRYAB also leads to significant reduction of inflammatory macrophages at day 3 after SCI
but does not altered the anti-inflammatory macrophage population (n 4 per group and time point). *p 0.05. Error bars indicate SEM.
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IL-6, KC/CXCL1, MIG/CXCL9, IP-10/
CXCL10, and MCP-1/CCL2), which are
mainly synthesized by astrocytes in SCI
(Pineau and Lacroix, 2007; Pineau et al.,
2010). Our data suggest that exogenous
rhCRYAB may stimulate astrocytes to in-
crease the expression of cytokines and
chemokines in SCI, as previously demon-
strated in microglia (van Noort et al.,
2010). Although we did not observe rh-
CRYAB in microglial cells, we cannot ex-
clude the possibility that microglia may
uptake low amounts of rhCRYAB after
SCI and contribute to the increased levels of
cytokines and chemokines observed after
rhCRYAB administration. We also ob-
served thatmice treatedwith rhCRYABhad
less astrogliosis at day 28 postinjury.
Whether this effect ismediated by the direct
action of CRYAB on astrocytes is not
known; however, transgenic expression of
CRYAB in astrocytes is reported to reduce
astrocyte hypertrophy in Alexander’s dis-
ease (Hagemannetal., 2009).Thus,ourdata
suggest that administration of rhCRYAB
enhances early activation of astrocytes fol-
lowing SCI, but reduces astrogliosis at late
stages. Similar effects have been observed in
after SCI in TLR4-null mice (Kigerl et al.,
2007). Although the lack of TLR4 led to a
marked reduction in the expressionof some
inflammatory triggers such as IL-1 early
after SCI, it also resulted ingreater astroglio-
sis (Kigerl et al., 2007).
Cytokines and chemokines trigger the recruitment and acti-
vation of immune cells. Our results show rhCRYAB treatment
resulted in an increase of granulocytes at day 1 postlesion, but not
at later time points. The contribution of granulocytes in SCI is a
subject of debate. Several studies have reported that granulocytes
play a detrimental role after SCI because blocking their recruit-
ment or activity following lesion leads to reduced tissue damage
(Taoka et al., 1997; Díaz-Ruiz et al., 2002; Naruo et al., 2003).
However, since these treatments do not exclusively reduce gran-
ulocytes, but also monocytes and microglia, it is difficult to attri-
bute these beneficial effects entirely to granulocytes. Recently,
depletion of granulocytes with anti-Ly6G/Gr-1 antibody was re-
ported to impair woundhealing and lead to greater tissue damage
and functional deficits after SCI, suggesting a protective role for
neutrophils in SCI (Stirling et al., 2009). Granulocytes and reac-
tive astrocytes are the main cell sources of secretory leukocyte
protease inhibitor at early stages after SCI, an enzyme that pro-
motes tissue healing and dampens inflammation (Taggart et al.,
2005), and that mediates protection in SCI (Ghasemlou et al.,
2010), which may explain, in part, the beneficial effects of gran-
ulocytes. However, a recent work shows that depletion of granu-
locytes before injury by Ly6G/Gr-1 antibody administration had
no effect on functional and histological outcomes (Lee et al.,
2011). Interestingly, the same study revealed that depletion of
Figure 7. Effects of recombinant human CRYAB treatment on astrogliosis.A, Graph showing quantitative analysis of GFAP immunoreactivity area at the lateral whitematter of the spinal cord at
day 28 postinjury. B, C, Representative micrographs of the lateral funiculus stained for GFAP frommice treated with saline (B) or CRYAB (C) taken at 180m rostral to injury epicenter.
Figure 8. Locomotor recovery and tissue sparing inmice treatedwith recombinant human CRYAB starting 6 and 12 h after SCI.
A, BMS scores of locomotor skills show that recombinant human CRYAB treatment started after a delay of 6 h following SCI also
promoted significant improvement in locomotor recovery. B, After a 12 h delay in the start of treatment, there was a significant
improvement in locomotor score fromday5 to14, but this effectwasnot sustainedat later timepoints.C,D, Quantificationof tissue
sparing in mice treated with rhCRYAB at 6 h (C) or 12 h (D) postinjury. *p 0.05. Error bars indicate SEM.
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neutrophils before SCI promoted neurological recovery only if
monocytes were also depleted from circulation (Lee et al., 2011).
These studies therefore suggest that neutrophils may exert either
helpful, harmful, or no effects in SCI depending on the presence
or their interactions with other immune cells such as macro-
phages. However, since the Ly6G/Gr-1 antibody also recognizes
Ly6C found on inflammatory but not in resident monocyte sub-
sets (David and Kroner, 2011), it is possible that the divergent
effects of the Ly6G/Gr-1 antibody may be due to a difference in
the efficacy of the treatment to deplete the Ly6C inflammatory
macrophages when given before and after SCI.
Studies performed in muscle injury have shown that Ly6C
macrophages exhibit phagocytic, proteolytic, and inflammatory
functions, whereas Ly6Cmacrophages release anti-inflammatory
cytokines and promote wound healing and repair (Arnold et al.,
2007;Nahrendorf et al., 2007). Interestingly, prevention of the accu-
mulation of Ly6C inflammatorymacrophages in sites of inflam-
mation reduces infarct size after coronary artery occlusion,
prolongs normoglycemia in diabetic mice after pancreatic islet
transplantation, and results in reduced tumor volumes (Leusch-
ner et al., 2011), suggesting a crucial role for inflammatory mac-
rophages in the course of many pathological conditions. These
two populations of macrophages have been also described in SCI
(Pineau et al., 2010). We observed that rhCRYAB treatment re-
duced the recruitment of Ly6C inflammatory macrophages
into the injured spinal cord at 3 d following lesion, when this
population peaked, but did not alter the accumulation of resident
macrophage subset. Recent studies also revealed that a subset of
macrophages, which express LyC6 but share some features of the
resident macrophages, such as the expression of CX3CR1, have
anti-inflammatory and neuroprotective properties (Shechter et
al., 2009; London et al., 2011). Herein we observe an increase in
granulocytes and a reduction of Ly6C inflammatory macro-
phages after rhCRYAB treatment. Therefore, the beneficial ef-
fects of CRYAB could be due to the effects on one or both of these
Gr1 cell populations.
Although further studies are needed to determine the optimal
dose of CRYAB, our data provides evidence that administration
of rhCRYAB after SCImodulates the inflammatory response and
results in reduced secondary damage and functional impairment.
In contrast to current anti-inflammatory therapies such as meth-
ylprednisolone or minocycline, among others, which broadly
block the inflammatory response (Kwon et al., 2011), the admin-
istration of rhCRYAB seems to increase some early aspects of
inflammation, such as cytokine/chemokine production and
granulocytes recruitment, while reducing some delayed aspects,
such as the infiltration of inflammatory macrophages. Since rh-
CRYAB treatment improved functional recovery when given
within 1–6 h after SCI, but not when delayed longer, early
changes in cytokine and chemokine expression observed upon
rhCRYAB treatment may be crucial to conferring protection.
Overall, this study shows for the first time that CRYAB plays a
beneficial role in SCI. Since rhCRYAB is effective even when
treatment is delayed for 6 h after contusion injury, it could be a
good therapeutic candidate for acute SCI in human, for which
there is currently no effective treatment.
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